Literature DB >> 18775370

Developing drugs for core social and communication impairment in autism.

David J Posey1, Craig A Erickson, Christopher J McDougle.   

Abstract

There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18775370      PMCID： PMC2566849          DOI： 10.1016/j.chc.2008.06.010

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN： 1056-4993


  59 in total

1.  Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.

Authors:  C J McDougle; L E Kresch; D J Posey
Journal:  J Autism Dev Disord       Date:  2000-10

2.  Risperidone in the treatment of two very young children with autism.

Authors:  D J Posey; K H Walsh; G A Wilson; C J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  1999       Impact factor: 2.576

3.  Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers.

Authors:  E R Ritvo; B J Freeman; A Yuwiler; E Geller; P Schroth; A Yokota; A Mason-Brothers; G J August; W Klykylo; B Leventhal
Journal:  Psychopharmacol Bull       Date:  1986

4.  Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities.

Authors:  B H King; D M Wright; M Snape; C T Dourish
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-06       Impact factor: 8.829

5.  Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

Authors:  B H King; D M Wright; B L Handen; L Sikich; A W Zimmerman; W McMahon; E Cantwell; P A Davanzo; C T Dourish; E M Dykens; S R Hooper; C A Jaselskis; B L Leventhal; J Levitt; C Lord; M J Lubetsky; S M Myers; S Ozonoff; B G Shah; M Snape; E W Shernoff; K Williamson; E H Cook
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-06       Impact factor: 8.829

6.  Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  K M Belsito; P A Law; K S Kirk; R J Landa; A W Zimmerman
Journal:  J Autism Dev Disord       Date:  2001-04

Review 7.  Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.

Authors:  C J McDougle; L Scahill; J T McCracken; M G Aman; E Tierney; L E Arnold; B J Freeman; A Martin; J J McGough; P Cronin; D J Posey; M A Riddle; L Ritz; N B Swiezy; B Vitiello; F R Volkmar; N A Votolato; P Walson
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2000-01

8.  Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.

Authors:  R P Malone; J Cater; R M Sheikh; M S Choudhury; M A Delaney
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-08       Impact factor: 8.829

9.  Pervasive developmental disorders in preschool children.

Authors:  S Chakrabarti; E Fombonne
Journal:  JAMA       Date:  2001-06-27       Impact factor: 56.272

10.  Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.

Authors:  Uriel Heresco-Levy; Marina Ermilov; Jonathan Shimoni; Baruch Shapira; Gail Silipo; Daniel C Javitt
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112
View more
  27 in total

Review 1.  Stimulus overselectivity four decades later: a review of the literature and its implications for current research in autism spectrum disorder.

Authors:  Bertram O Ploog
Journal:  J Autism Dev Disord       Date:  2010-11

2.  Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders.

Authors:  Tin-Lap Lee; Margarita J Raygada; Owen M Rennert
Journal:  Gene       Date:  2012-01-26       Impact factor: 3.688

Review 3.  Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with families.

Authors:  R Scott Akins; Kathy Angkustsiri; Robin L Hansen
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 5.  Autism.

Authors:  Susan E Levy; David S Mandell; Robert T Schultz
Journal:  Lancet       Date:  2009-10-12       Impact factor: 79.321

6.  Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.

Authors:  Craig A Erickson; Logan K Wink; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2014-04

7.  An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

Authors:  Craig A Erickson; Maureen Early; Kimberly A Stigler; Logan K Wink; Jennifer E Mullett; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-02       Impact factor: 2.576

Review 8.  Issues in the management of challenging behaviours of adults with autism spectrum disorder.

Authors:  Johnny L Matson; Megan Sipes; Jill C Fodstad; Mary E Fitzgerald
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

9.  Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.

Authors:  Lawrence Scahill; Victoria Hallett; Michael G Aman; Christopher J McDougle; L Eugene Arnold; James T McCracken; Elaine Tierney; Yanhong Deng; James Dziura; Benedetto Vitiello
Journal:  J Autism Dev Disord       Date:  2013-03

Review 10.  Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.

Authors:  Cristan Farmer; Audrey Thurm; Paul Grant
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.